Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPM787000048 Maleate Sustained-Release Tablets in Acute Schizophrenia (Phase II)
CTR20260156Phase 2Active
- Sponsor
- Luye Pharma Group
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lpm787000048 maleate in schizophrenia (4 arms), sponsored by Luye Pharma Group. Primary endpoint: Change from baseline in PANSS total score at Week 6 of maintenance treatment. Started Mar 2026; status: active.
02
Drugs
lpm787000048 maleate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20260156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260156.